Darzalex (Daratumumab) PK Simulator
Indication: Multiple myeloma
Simulate Darzalex (daratumumab) pharmacokinetics. This PK simulator models the anti-CD38 monoclonal antibody used in the treatment of multiple myeloma.
Drug Overview
Clinical Context
- Molecular Target
- CD38
- Drug Class
- mAb
- Therapeutic Area
- Oncology
- Indication
- Multiple myeloma
- Route of Administration
- IV
Model Information
- Model Type
- 2-CMT PopPK
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
About This Simulator
This interactive pharmacokinetic simulator for Darzalex (Daratumumab) allows you to explore concentration-time profiles under different dosing scenarios. The underlying 2-CMT PopPK model characterizes the pharmacokinetics of this mab following iv administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration).
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the Darzalex (Daratumumab) PK simulator?
This is a free, interactive pharmacokinetic simulator for Darzalex (Daratumumab) used in Multiple myeloma. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does Darzalex (Daratumumab) belong to?
Darzalex (Daratumumab) is classified as a mAb that targets CD38. It is used in the Oncology therapeutic area.
What route of administration does this model simulate?
This simulator models IV administration of Darzalex (Daratumumab). The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a 2-CMT PopPK model. Population PK models account for interindividual variability and covariate effects on drug exposure.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
Related Simulators
G-CSF Effects in Carboplatin-Treated Cancer Patients
Chemotherapy-induced neutropenia
Methotrexate population PK in Mexican pediatric ALL
Acute lymphoblastic leukemia in pediatric patients receiving high-dose methotrexate
Population PKPD
Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC), HR+/HER2-negative metastatic breast cancer after endocrine and CDK4/6 inhibitor therapy, and locally advanced or metastatic urothelial cancer
Tamoxifen
Hormone receptor-positive breast cancer adjuvant therapy
Pertuzumab
HER2-positive solid tumors
Serplulimab (HLX10) Population PK Simulator
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Ready to Simulate?
Launch the Darzalex (Daratumumab) simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community